Actavis' (ACT) DUR001-303 Study Meets Primary & Secondary Endpoints
Tweet Send to a Friend
Actavis plc (NYSE: ACT) today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
